Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a new class of medicines known as Endosomal Escape Vehicle (EEV™)-therapeutics. Founded in 2016 by 5AM Ventures, Entrada aims to make previously inaccessible intracellular targets reachable, thereby opening new avenues for treating serious diseases.
Entrada Therapeutics is pioneering the delivery of a wide range of therapeutics to various organs and tissues, thereby improving the therapeutic index. The company's portfolio includes programs targeting neuromuscular diseases, immunological disorders, and metabolic conditions, amongst others.
One of the company's most promising candidates is ENTR-601-44, which is being developed to treat Duchenne muscular dystrophy (DMD), particularly in patients who are exon 44 skipping amenable. The ongoing Phase 1 clinical trial for ENTR-601-44 aims to evaluate the safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers. This trial has already enrolled its first participants, with data anticipated in the second half of 2024.
Recent Achievements:In recent news, Entrada Therapeutics received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and the Research Ethics Committee (REC) to conduct its Phase 1 clinical trial of ENTR-601-44. Additionally, the company reported robust financial results for the third quarter of 2023, with significant cash reserves and collaboration revenue marking crucial steps in their growth trajectory.
Strategic Milestones:Entrada Therapeutics is well-positioned to continue its strategic initiatives through 2025, thanks to its strong financial footing and ongoing collaborations. The company has also recently appointed Nathan J. Dowden as President and Chief Operating Officer, further strengthening its executive team.
Beyond its lead program, Entrada's pipeline includes several other candidates aimed at treating various subtypes of DMD and myotonic dystrophy type 1 (DM1). These developments underscore Entrada's commitment to advancing its modular EEV platform to address a broad spectrum of unmet medical needs.
For more detailed and up-to-date information about Entrada Therapeutics, please visit their official website and follow them on LinkedIn.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced a clinical hold from the FDA on its IND application for ENTR-601-44, aimed at treating Duchenne muscular dystrophy. The FDA's formal Clinical Hold letter will be issued within 30 days. CEO Dipal Doshi expressed disappointment but is committed to addressing the FDA's concerns. The hold is significant as there are currently no approved therapies for patients with exon 44 skippable mutations in Duchenne. Further updates will follow as Entrada engages with the FDA.
Vertex Pharmaceuticals (VRTX) and Entrada Therapeutics (TRDA) have announced a global collaboration to develop intracellular EEV therapeutics for myotonic dystrophy type 1 (DM1). Entrada will receive an upfront payment of
Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, at 3:55 PM ET. This event highlights Entrada's commitment to revolutionizing medicine through its Endosomal Escape Vehicle (EEVTM) therapeutics, targeting previously inaccessible intracellular diseases. The chat will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days post-event.
Entrada Therapeutics (Nasdaq: TRDA) reported financial results for Q3 2022, with a net loss of $25.1 million compared to $14.4 million in Q3 2021. As of September 30, 2022, the company had $216 million in cash and equivalents, projected to fund operations into 2H 2024. The company is on track to submit an IND for ENTR-601-44 for Duchenne muscular dystrophy by Q4 2022 and plans to initiate a single ascending dose study in 2023. R&D expenses rose to $19 million from $10.5 million a year prior, driven by increased preclinical study investments.
Entrada Therapeutics (Nasdaq: TRDA) announced that Nathan Dowden, Chief Operating Officer, will virtually present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be accessible starting September 12, 2022, at 7:00 a.m. Eastern Time on the company's website. A replay will be available for 90 days after the event. Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics for treating diseases including Duchenne muscular dystrophy and myotonic dystrophy.
Entrada Therapeutics (Nasdaq: TRDA) announced that it is on track to submit an Investigational New Drug (IND) application for ENTR-601-44, targeting Duchenne muscular dystrophy (DMD), in Q4 2022. The company holds $244 million in cash and equivalents, ensuring a cash runway into 2H 2024. R&D expenses surged to $16.2 million from $6.8 million year-over-year, with a net loss of $23.2 million for Q2 2022. Entrada also presented promising preclinical data for its therapeutic candidates and initiated collaborations aimed at accelerating developments in neuromuscular disease treatments.
Entrada Therapeutics (Nasdaq: TRDA) has announced a collaboration with the Myotonic Dystrophy Clinical Research Network (DMCRN) to support the END-DM1 study, which aims to understand disease progression in myotonic dystrophy type 1 (DM1). This non-interventional study will provide critical data for future clinical trials. Entrada's clinical candidate, ENTR-701, is being developed to potentially treat DM1, with new preclinical data indicating improved therapeutic effects in mouse models. The company plans to file an IND application for ENTR-701 in 2023.
Entrada Therapeutics (Nasdaq: TRDA) announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald, previously the Vice President of Corporate Communications and Investor Relations, will report to Dipal Doshi, President and CEO. Her extensive experience in biopharmaceutical communications and stakeholder engagement supports Entrada's focus on developing Endosomal Escape Vehicle (EEV™) therapeutics, particularly for neuromuscular diseases like Duchenne muscular dystrophy. The company is transitioning into a clinical stage entity this year.
Entrada Therapeutics (Nasdaq: TRDA) announced its participation at the William Blair Biotech Focus Conference in New York on July 12-13, 2022. A fireside chat featuring Dipal Doshi and Natarajan Sethuraman will be available for viewing starting July 11, 2022, at 9:00 a.m. ET on the company’s website, with a 90-day replay. Entrada focuses on developing Endosomal Escape Vehicle (EEV™) therapeutics to target previously inaccessible intracellular sites, targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy.
Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company focused on advancing Endosomal Escape Vehicle (EEV™) therapeutics, announced its participation in the Goldman Sachs Global Healthcare Conference. The event will feature a fireside chat with President and CEO Dipal Doshi on June 14, 2022, at 2:40 p.m. PT in Rancho Palos Verdes, CA. A live webcast will be available on the company’s website, with a replay accessible for 90 days afterward.
FAQ
What is the current stock price of Entrada Therapeutics (TRDA)?
What is the market cap of Entrada Therapeutics (TRDA)?
What is Entrada Therapeutics' core business?
What is ENTR-601-44?
What recent milestones has Entrada Therapeutics achieved?
What is the aim of the ongoing clinical trial for ENTR-601-44?
Who founded Entrada Therapeutics?
What diseases does Entrada Therapeutics aim to treat?
How is Entrada Therapeutics funded?
Who is the current CEO of Entrada Therapeutics?
Where can I find more information about Entrada Therapeutics?
What is the significance of the EEV™ platform?
